| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thyroid Neoplasms | 30 | 2023 | 250 | 8.170 |
Why?
|
| Thyroidectomy | 18 | 2024 | 102 | 4.430 |
Why?
|
| Parathyroidectomy | 17 | 2023 | 50 | 3.520 |
Why?
|
| Carcinoma, Papillary | 11 | 2023 | 93 | 2.610 |
Why?
|
| Natural Orifice Endoscopic Surgery | 5 | 2024 | 72 | 1.990 |
Why?
|
| Parathyroid Hormone | 9 | 2019 | 83 | 1.750 |
Why?
|
| Thyroid Gland | 8 | 2023 | 104 | 1.700 |
Why?
|
| Carcinoma | 6 | 2016 | 299 | 1.620 |
Why?
|
| Hyperparathyroidism, Primary | 10 | 2023 | 34 | 1.570 |
Why?
|
| Endocrine Surgical Procedures | 3 | 2021 | 6 | 1.450 |
Why?
|
| Recurrent Laryngeal Nerve Injuries | 3 | 2021 | 15 | 1.370 |
Why?
|
| Parathyroid Neoplasms | 6 | 2016 | 24 | 1.260 |
Why?
|
| Hypocalcemia | 4 | 2018 | 38 | 1.250 |
Why?
|
| Hyperparathyroidism, Secondary | 3 | 2018 | 18 | 1.210 |
Why?
|
| Adrenal Gland Neoplasms | 4 | 2016 | 79 | 1.180 |
Why?
|
| Thyroid Nodule | 3 | 2018 | 22 | 1.170 |
Why?
|
| Adrenalectomy | 4 | 2019 | 40 | 1.130 |
Why?
|
| Parathyroid Glands | 5 | 2023 | 29 | 1.120 |
Why?
|
| Adenocarcinoma, Follicular | 6 | 2017 | 15 | 1.040 |
Why?
|
| Adenoma | 5 | 2015 | 146 | 1.020 |
Why?
|
| Quality of Life | 7 | 2024 | 2157 | 1.010 |
Why?
|
| Survivors | 3 | 2016 | 354 | 0.910 |
Why?
|
| Robotic Surgical Procedures | 3 | 2019 | 222 | 0.900 |
Why?
|
| Calcium | 7 | 2019 | 1078 | 0.900 |
Why?
|
| Pathologists | 1 | 2022 | 26 | 0.780 |
Why?
|
| Pancreatic Neoplasms | 3 | 2021 | 728 | 0.770 |
Why?
|
| Hyperaldosteronism | 2 | 2019 | 17 | 0.750 |
Why?
|
| Hypoparathyroidism | 1 | 2021 | 11 | 0.730 |
Why?
|
| Postoperative Complications | 6 | 2018 | 3139 | 0.710 |
Why?
|
| Middle Aged | 36 | 2024 | 28943 | 0.700 |
Why?
|
| Male | 49 | 2024 | 64870 | 0.630 |
Why?
|
| Physicians | 2 | 2018 | 641 | 0.620 |
Why?
|
| Female | 51 | 2024 | 70584 | 0.620 |
Why?
|
| Calcium Gluconate | 1 | 2018 | 6 | 0.600 |
Why?
|
| Endocrine System Diseases | 1 | 2019 | 43 | 0.600 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2015 | 767 | 0.590 |
Why?
|
| Medical History Taking | 1 | 2019 | 114 | 0.590 |
Why?
|
| Calcitriol | 1 | 2018 | 65 | 0.580 |
Why?
|
| Breast Neoplasms | 3 | 2016 | 2645 | 0.570 |
Why?
|
| Adult | 31 | 2024 | 31536 | 0.570 |
Why?
|
| Humans | 64 | 2024 | 131924 | 0.560 |
Why?
|
| Cancer Survivors | 2 | 2018 | 249 | 0.540 |
Why?
|
| Social Perception | 1 | 2018 | 56 | 0.540 |
Why?
|
| Aged | 23 | 2023 | 21385 | 0.520 |
Why?
|
| Preoperative Care | 2 | 2018 | 367 | 0.510 |
Why?
|
| Ultrasonic Surgical Procedures | 1 | 2016 | 2 | 0.510 |
Why?
|
| Postoperative Care | 1 | 2018 | 312 | 0.500 |
Why?
|
| Electrosurgery | 1 | 2016 | 17 | 0.500 |
Why?
|
| SEER Program | 5 | 2016 | 220 | 0.490 |
Why?
|
| Travel | 1 | 2017 | 124 | 0.490 |
Why?
|
| Gastric Bypass | 1 | 2016 | 80 | 0.470 |
Why?
|
| Spirituality | 1 | 2015 | 50 | 0.470 |
Why?
|
| Biopsy, Fine-Needle | 4 | 2018 | 119 | 0.470 |
Why?
|
| Disease Management | 1 | 2019 | 562 | 0.460 |
Why?
|
| Intraoperative Complications | 1 | 2016 | 161 | 0.460 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2017 | 168 | 0.460 |
Why?
|
| Incidence | 9 | 2018 | 3375 | 0.450 |
Why?
|
| Epigenomics | 1 | 2016 | 191 | 0.450 |
Why?
|
| Medical Errors | 1 | 2016 | 161 | 0.450 |
Why?
|
| Lymphatic Metastasis | 4 | 2017 | 442 | 0.440 |
Why?
|
| Incidental Findings | 3 | 2015 | 129 | 0.440 |
Why?
|
| Rare Diseases | 2 | 2016 | 209 | 0.440 |
Why?
|
| Pheochromocytoma | 2 | 2011 | 38 | 0.430 |
Why?
|
| Biological Assay | 1 | 2014 | 111 | 0.430 |
Why?
|
| Graves Disease | 1 | 2014 | 13 | 0.430 |
Why?
|
| Social Behavior | 1 | 2015 | 223 | 0.420 |
Why?
|
| Obesity, Morbid | 1 | 2016 | 210 | 0.420 |
Why?
|
| Neck Dissection | 3 | 2019 | 31 | 0.410 |
Why?
|
| Health Status | 1 | 2015 | 407 | 0.410 |
Why?
|
| Laparoscopy | 2 | 2018 | 523 | 0.410 |
Why?
|
| Hypertension | 2 | 2019 | 1396 | 0.400 |
Why?
|
| Mass Screening | 1 | 2018 | 828 | 0.380 |
Why?
|
| Health Services Accessibility | 2 | 2017 | 669 | 0.370 |
Why?
|
| Chicago | 3 | 2016 | 21 | 0.350 |
Why?
|
| DNA Methylation | 2 | 2023 | 1122 | 0.330 |
Why?
|
| Prognosis | 9 | 2023 | 5007 | 0.320 |
Why?
|
| Adenocarcinoma | 1 | 2017 | 1015 | 0.320 |
Why?
|
| Muscle, Skeletal | 1 | 2016 | 1034 | 0.310 |
Why?
|
| Neoplasm Staging | 5 | 2017 | 1361 | 0.310 |
Why?
|
| Case-Control Studies | 4 | 2019 | 3409 | 0.310 |
Why?
|
| Nuclear Proteins | 1 | 2015 | 1280 | 0.310 |
Why?
|
| Follow-Up Studies | 6 | 2016 | 5408 | 0.310 |
Why?
|
| Cohort Studies | 8 | 2018 | 5163 | 0.300 |
Why?
|
| Survival Rate | 6 | 2016 | 2186 | 0.300 |
Why?
|
| Liver | 1 | 2016 | 1796 | 0.300 |
Why?
|
| Genome-Wide Association Study | 1 | 2016 | 1829 | 0.290 |
Why?
|
| Age Factors | 5 | 2016 | 2912 | 0.280 |
Why?
|
| Retrospective Studies | 17 | 2019 | 17374 | 0.280 |
Why?
|
| Biomarkers, Tumor | 1 | 2016 | 1657 | 0.270 |
Why?
|
| Clinical Competence | 1 | 2014 | 1068 | 0.260 |
Why?
|
| Sex Factors | 3 | 2015 | 1351 | 0.240 |
Why?
|
| Technetium Tc 99m Sestamibi | 3 | 2014 | 26 | 0.220 |
Why?
|
| Practice Guidelines as Topic | 3 | 2018 | 1299 | 0.220 |
Why?
|
| United States | 7 | 2019 | 11648 | 0.220 |
Why?
|
| Terminology as Topic | 2 | 2015 | 232 | 0.210 |
Why?
|
| Young Adult | 9 | 2016 | 9952 | 0.190 |
Why?
|
| Nephrolithiasis | 2 | 2011 | 15 | 0.180 |
Why?
|
| Endoscopy | 2 | 2021 | 288 | 0.180 |
Why?
|
| Risk Factors | 6 | 2016 | 10933 | 0.180 |
Why?
|
| False Negative Reactions | 2 | 2018 | 89 | 0.170 |
Why?
|
| Prospective Studies | 4 | 2024 | 6569 | 0.170 |
Why?
|
| Aged, 80 and over | 5 | 2016 | 7097 | 0.170 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2016 | 1304 | 0.170 |
Why?
|
| Time Factors | 3 | 2016 | 6440 | 0.170 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2013 | 1127 | 0.170 |
Why?
|
| Ultrasonography | 5 | 2017 | 986 | 0.160 |
Why?
|
| Registries | 3 | 2018 | 1579 | 0.160 |
Why?
|
| Cicatrix | 1 | 2021 | 121 | 0.160 |
Why?
|
| Lymph Node Excision | 2 | 2017 | 174 | 0.150 |
Why?
|
| Cognitive Dysfunction | 1 | 2023 | 316 | 0.150 |
Why?
|
| Clinical Chemistry Tests | 1 | 2019 | 5 | 0.150 |
Why?
|
| Hypercalcemia | 1 | 2019 | 42 | 0.150 |
Why?
|
| Radiopharmaceuticals | 3 | 2014 | 170 | 0.150 |
Why?
|
| Publication Bias | 1 | 2018 | 17 | 0.150 |
Why?
|
| Hypokalemia | 1 | 2018 | 42 | 0.150 |
Why?
|
| Immunoassay | 1 | 2019 | 135 | 0.140 |
Why?
|
| Severity of Illness Index | 3 | 2016 | 3087 | 0.140 |
Why?
|
| Risk Adjustment | 1 | 2018 | 58 | 0.140 |
Why?
|
| Infusions, Intravenous | 1 | 2018 | 547 | 0.130 |
Why?
|
| Hematoma | 1 | 2018 | 92 | 0.130 |
Why?
|
| Surveys and Questionnaires | 4 | 2024 | 3990 | 0.130 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2016 | 81 | 0.120 |
Why?
|
| Adolescent | 7 | 2016 | 20535 | 0.120 |
Why?
|
| Antihypertensive Agents | 1 | 2019 | 429 | 0.120 |
Why?
|
| Body Temperature | 1 | 2016 | 128 | 0.120 |
Why?
|
| Guideline Adherence | 1 | 2018 | 393 | 0.120 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2016 | 63 | 0.120 |
Why?
|
| Global Health | 2 | 2018 | 643 | 0.120 |
Why?
|
| Treatment Outcome | 5 | 2019 | 12991 | 0.120 |
Why?
|
| Predictive Value of Tests | 3 | 2017 | 2311 | 0.120 |
Why?
|
| Reference Values | 1 | 2016 | 704 | 0.120 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 333 | 0.120 |
Why?
|
| Multivariate Analysis | 2 | 2015 | 1439 | 0.120 |
Why?
|
| Four-Dimensional Computed Tomography | 1 | 2014 | 12 | 0.110 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2018 | 234 | 0.110 |
Why?
|
| Frozen Sections | 1 | 2014 | 30 | 0.110 |
Why?
|
| Hyperostosis Frontalis Interna | 1 | 2014 | 3 | 0.110 |
Why?
|
| Finland | 1 | 2014 | 46 | 0.110 |
Why?
|
| Hospitals | 1 | 2018 | 438 | 0.110 |
Why?
|
| Canada | 1 | 2015 | 337 | 0.110 |
Why?
|
| CpG Islands | 1 | 2016 | 343 | 0.110 |
Why?
|
| Educational Status | 1 | 2015 | 294 | 0.110 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 485 | 0.110 |
Why?
|
| Qualitative Research | 1 | 2018 | 664 | 0.110 |
Why?
|
| Tertiary Care Centers | 1 | 2015 | 256 | 0.110 |
Why?
|
| Monitoring, Intraoperative | 1 | 2014 | 132 | 0.110 |
Why?
|
| Age of Onset | 1 | 2015 | 622 | 0.110 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 448 | 0.110 |
Why?
|
| Social Class | 1 | 2015 | 206 | 0.100 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2013 | 11 | 0.100 |
Why?
|
| Linear Models | 1 | 2015 | 713 | 0.100 |
Why?
|
| Psychometrics | 1 | 2017 | 686 | 0.100 |
Why?
|
| Communication | 1 | 2018 | 542 | 0.100 |
Why?
|
| Germ-Line Mutation | 1 | 2015 | 368 | 0.100 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 308 | 0.100 |
Why?
|
| Blood Pressure | 1 | 2019 | 1400 | 0.100 |
Why?
|
| Activities of Daily Living | 1 | 2015 | 428 | 0.100 |
Why?
|
| Swine | 1 | 2016 | 1180 | 0.100 |
Why?
|
| Regression Analysis | 1 | 2014 | 795 | 0.100 |
Why?
|
| Cross-Sectional Studies | 2 | 2019 | 3760 | 0.100 |
Why?
|
| Length of Stay | 1 | 2018 | 1380 | 0.100 |
Why?
|
| ROC Curve | 1 | 2014 | 600 | 0.100 |
Why?
|
| Analysis of Variance | 1 | 2014 | 1011 | 0.100 |
Why?
|
| Costs and Cost Analysis | 1 | 2013 | 166 | 0.100 |
Why?
|
| Genetic Testing | 1 | 2019 | 1098 | 0.090 |
Why?
|
| Attitude of Health Personnel | 1 | 2018 | 724 | 0.090 |
Why?
|
| Health Status Disparities | 1 | 2015 | 253 | 0.090 |
Why?
|
| Comorbidity | 1 | 2017 | 1605 | 0.090 |
Why?
|
| Hypercalciuria | 1 | 2011 | 8 | 0.090 |
Why?
|
| Logistic Models | 1 | 2016 | 1839 | 0.090 |
Why?
|
| 3-Iodobenzylguanidine | 1 | 2011 | 12 | 0.090 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2010 | 5 | 0.090 |
Why?
|
| Cost of Illness | 1 | 2013 | 284 | 0.090 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 1693 | 0.090 |
Why?
|
| Azacitidine | 1 | 2010 | 53 | 0.090 |
Why?
|
| Cell Line, Tumor | 2 | 2015 | 3678 | 0.080 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2010 | 86 | 0.080 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2010 | 22 | 0.080 |
Why?
|
| Body Mass Index | 1 | 2016 | 1696 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2015 | 2166 | 0.080 |
Why?
|
| Risk Assessment | 2 | 2016 | 3732 | 0.080 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 845 | 0.080 |
Why?
|
| Health Care Costs | 1 | 2013 | 414 | 0.080 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2010 | 193 | 0.080 |
Why?
|
| Prevalence | 1 | 2015 | 2658 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 1 | 2011 | 396 | 0.070 |
Why?
|
| Catheter Ablation | 1 | 2011 | 263 | 0.070 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2010 | 339 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 2850 | 0.060 |
Why?
|
| Kidney Failure, Chronic | 1 | 2014 | 950 | 0.060 |
Why?
|
| Quality Improvement | 1 | 2012 | 699 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 3351 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 1949 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 2 | 2017 | 663 | 0.050 |
Why?
|
| Lymph Nodes | 2 | 2017 | 389 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 3829 | 0.050 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2015 | 194 | 0.050 |
Why?
|
| Radionuclide Imaging | 2 | 2014 | 144 | 0.050 |
Why?
|
| Israel | 1 | 2021 | 48 | 0.040 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2023 | 221 | 0.040 |
Why?
|
| Public Opinion | 1 | 2021 | 62 | 0.040 |
Why?
|
| Mouth | 1 | 2021 | 67 | 0.040 |
Why?
|
| Operative Time | 1 | 2021 | 192 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2021 | 356 | 0.040 |
Why?
|
| Child | 3 | 2015 | 25761 | 0.040 |
Why?
|
| Recurrence | 2 | 2014 | 1452 | 0.040 |
Why?
|
| Intraoperative Period | 1 | 2019 | 69 | 0.040 |
Why?
|
| Systole | 1 | 2019 | 206 | 0.040 |
Why?
|
| Diastole | 1 | 2019 | 181 | 0.040 |
Why?
|
| Delayed Diagnosis | 1 | 2019 | 133 | 0.030 |
Why?
|
| DNA | 1 | 2023 | 1472 | 0.030 |
Why?
|
| Time-to-Treatment | 1 | 2019 | 210 | 0.030 |
Why?
|
| Video-Assisted Surgery | 1 | 2015 | 5 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2016 | 247 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2019 | 568 | 0.030 |
Why?
|
| Animals | 1 | 2016 | 34781 | 0.030 |
Why?
|
| California | 1 | 2015 | 139 | 0.030 |
Why?
|
| Thymectomy | 1 | 2014 | 23 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 306 | 0.030 |
Why?
|
| Insurance, Health | 1 | 2015 | 144 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2016 | 958 | 0.030 |
Why?
|
| Consensus | 1 | 2017 | 649 | 0.030 |
Why?
|
| Neoplasms, Second Primary | 1 | 2015 | 149 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2018 | 1228 | 0.020 |
Why?
|
| Rural Population | 1 | 2015 | 239 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2015 | 286 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2017 | 777 | 0.020 |
Why?
|
| Kidney Calculi | 1 | 2012 | 49 | 0.020 |
Why?
|
| Muscle Weakness | 1 | 2012 | 91 | 0.020 |
Why?
|
| Calcium Oxalate | 1 | 2011 | 24 | 0.020 |
Why?
|
| Fatigue | 1 | 2012 | 202 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 1458 | 0.020 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 1 | 2010 | 17 | 0.020 |
Why?
|
| Hydroxamic Acids | 1 | 2010 | 60 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2010 | 111 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2010 | 90 | 0.020 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2010 | 44 | 0.020 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2010 | 137 | 0.020 |
Why?
|
| Abdominal Pain | 1 | 2012 | 314 | 0.020 |
Why?
|
| Valproic Acid | 1 | 2010 | 163 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 2140 | 0.020 |
Why?
|
| Mutation | 1 | 2023 | 6226 | 0.020 |
Why?
|
| Shock, Cardiogenic | 1 | 2010 | 177 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 2014 | 947 | 0.020 |
Why?
|
| Depression | 1 | 2012 | 1339 | 0.010 |
Why?
|
| Neoplasms | 1 | 2016 | 2955 | 0.010 |
Why?
|
| Infant | 1 | 2011 | 13047 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2011 | 14732 | 0.010 |
Why?
|